Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity.
Kleczko EK, Hinz TK, Nguyen TT, Gurule NJ, Navarro A, Le AT, Johnson AM, Kwak J, Polhac DI, Clambey ET, Weiser-Evans M, Merrick DT, Yang MC, Patil T, Schenk EL, Heasley LE, Nemenoff RA. Kleczko EK, et al. Among authors: schenk el. NPJ Precis Oncol. 2023 Feb 4;7(1):15. doi: 10.1038/s41698-023-00355-2. NPJ Precis Oncol. 2023. PMID: 36739466 Free PMC article.
Tumor-intrinsic response to IFNγ shapes the tumor microenvironment and anti-PD-1 response in NSCLC.
Bullock BL, Kimball AK, Poczobutt JM, Neuwelt AJ, Li HY, Johnson AM, Kwak JW, Kleczko EK, Kaspar RE, Wagner EK, Hopp K, Schenk EL, Weiser-Evans MC, Clambey ET, Nemenoff RA. Bullock BL, et al. Among authors: schenk el. Life Sci Alliance. 2019 May 27;2(3):e201900328. doi: 10.26508/lsa.201900328. Print 2019 Jun. Life Sci Alliance. 2019. PMID: 31133614 Free PMC article.
Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
Patil T, Mushtaq R, Marsh S, Azelby C, Pujara M, Davies KD, Aisner DL, Purcell WT, Schenk EL, Pacheco JM, Bunn PA, Camidge DR, Doebele RC. Patil T, et al. Among authors: schenk el. Clin Lung Cancer. 2020 May;21(3):e191-e204. doi: 10.1016/j.cllc.2019.11.008. Epub 2019 Nov 21. Clin Lung Cancer. 2020. PMID: 31859066 Free PMC article.
Cancer Cell-Intrinsic Expression of MHC Class II Regulates the Immune Microenvironment and Response to Anti-PD-1 Therapy in Lung Adenocarcinoma.
Johnson AM, Bullock BL, Neuwelt AJ, Poczobutt JM, Kaspar RE, Li HY, Kwak JW, Hopp K, Weiser-Evans MCM, Heasley LE, Schenk EL, Clambey ET, Nemenoff RA. Johnson AM, et al. Among authors: schenk el. J Immunol. 2020 Apr 15;204(8):2295-2307. doi: 10.4049/jimmunol.1900778. Epub 2020 Mar 16. J Immunol. 2020. PMID: 32179637 Free PMC article.
2020 Innovation-Based Optimism for Lung Cancer Outcomes.
Schenk EL, Patil T, Pacheco J, Bunn PA Jr. Schenk EL, et al. Oncologist. 2021 Mar;26(3):e454-e472. doi: 10.1002/onco.13590. Epub 2020 Dec 20. Oncologist. 2021. PMID: 33179378 Free PMC article. Review.
Cancer Cell-Specific Major Histocompatibility Complex II Expression as a Determinant of the Immune Infiltrate Organization and Function in the NSCLC Tumor Microenvironment.
Johnson AM, Boland JM, Wrobel J, Klezcko EK, Weiser-Evans M, Hopp K, Heasley L, Clambey ET, Jordan K, Nemenoff RA, Schenk EL. Johnson AM, et al. Among authors: schenk el. J Thorac Oncol. 2021 Oct;16(10):1694-1704. doi: 10.1016/j.jtho.2021.05.004. Epub 2021 May 25. J Thorac Oncol. 2021. PMID: 34048945 Free PMC article.
Evolution of acquired resistance in a ROS1+ KRAS G12C+ NSCLC through the MAPK pathway.
Priest K, Le A, Gebregzabheir A, Nijmeh H, Reis GB, Mandell M, Davies KD, Lawrence C, O'Donnell E, Doebele RC, Bao L, Aisner DL, Schenk EL. Priest K, et al. Among authors: schenk el. NPJ Precis Oncol. 2023 Jan 23;7(1):9. doi: 10.1038/s41698-023-00349-0. NPJ Precis Oncol. 2023. PMID: 36690705 Free PMC article.
38 results